Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Opinion in Oncology|February 1, 2023
Current "state of the art" on dendritic cell-based cancer vaccines in melanomaJulia Katharina Schwarze, Xenia Geeraerts, Sandra Tuyaerts, et al.
Frontiers in Immunology|April 1, 2017
Macrophage Metabolism As Therapeutic Target for Cancer, Atherosclerosis, and ObesityXenia Geeraerts, Evangelia Bolli, Sarah-Maria Fendt, et al.
Cellular Immunology|April 18, 2018
The role of hepatic macrophages in liver metastasisJiri Keirsse, Helena Van Damme, Xenia Geeraerts, et al.
Vaccines|May 26, 2026
Reinvigorating the Cancer-Immunity Cycle by Intratumoral Administration of Conventional Dendritic Cells in Melanoma and Other Solid Tumors: A Narrative ReviewManon Vounckx, Iris Dirven, Cleo Bertels, et al.
Molecular Therapy. Oncology|September 16, 2025
Oncolytic HSV-1 expressing FLT3L kills melanoma, glioblastoma, and pancreatic cancer cells <i>in vitro</i> and induces immunogenic cell deathSandra Tuyaerts, Xenia Geeraerts, Alberto Reale, et al.
Frontiers in Oncology|December 25, 2014
Myeloid-derived suppressor cells as therapeutic target in hematological malignanciesKim De Veirman, Els Van Valckenborgh, Qods Lahmar, et al.
Journal for Immunotherapy of Cancer|January 11, 2024
Intratumoral administration of the immunologic adjuvant AS01<sub>B</sub> in combination with autologous CD1c (BDCA-1)<sup>+</sup>/CD141 (BDCA-3)<sup>+</sup> myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanomaJens Tijtgat, Xenia Geeraerts, Anais Boisson, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 25, 2019
Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophagesYannick De Vlaeminck, Quentin Lecocq, Philippe Giron, et al.
The FEBS Journal|August 24, 2017
Beyond the M-CSF receptor - novel therapeutic targets in tumor-associated macrophagesStefano Bonelli, Xenia Geeraerts, Evangelia Bolli, et al.
Neuro-Oncology|October 15, 2024
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade gliomaJohnny Duerinck, Louise Lescrauwaet, Iris Dirven, et al.
Pageof 2